These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38953434)

  • 1. Reconstruction of the historic time course of blood-borne virus contamination of clotting factor concentrates, 1974-1992.
    McClure CP; Kean K; Reid K; Mayne R; Fu MX; Rajendra P; Gates S; Breuer J; Harvala H; Golubchik T; Tarr AW; Irving WL; Makris M; Simmonds P
    J Med Virol; 2024 Jul; 96(7):e29774. PubMed ID: 38953434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human parvovirus PARV4 in clotting factor VIII concentrates.
    Fryer JF; Hubbard AR; Baylis SA
    Vox Sang; 2007 Nov; 93(4):341-7. PubMed ID: 18070279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of nucleic acid sequences specific for human parvoviruses, hepatitis A and hepatitis E viruses in coagulation factor concentrates.
    Modrow S; Wenzel JJ; Schimanski S; Schwarzbeck J; Rothe U; Oldenburg J; Jilg W; Eis-Hübinger AM
    Vox Sang; 2011 May; 100(4):351-8. PubMed ID: 21133933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Seroprevalence of parvovirus B19, cytomegalovirus, hepatitis A virus and hepatitis E virus antibodies in haemophiliacs treated exclusively with clotting-factor concentrates considered safe against human immunodeficiency and hepatitis C viruses.
    Flores G; Juárez JC; Montoro JB; Tusell JM; Altisent C; Juste C; Jardí R
    Haemophilia; 1995 Apr; 1(2):115-7. PubMed ID: 27214319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Virologic and clinical features of primary infection with human parvovirus 4 in subjects with hemophilia: frequent transmission by virally inactivated clotting factor concentrates.
    Sharp CP; Lail A; Donfield S; Gomperts ED; Simmonds P
    Transfusion; 2012 Jul; 52(7):1482-9. PubMed ID: 22043925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Blood Transfusion on the Prevalence of HHpgV-1, HPgV-1, and B19V Among Iranian HCV-infected Patients With Hemophilia.
    Agi E; Hojjatipour S; Namvar A; Bolhassani A
    J Pediatr Hematol Oncol; 2020 May; 42(4):e213-e218. PubMed ID: 31972722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis G virus in clotting factor concentrates.
    Alonso-Rubiano E; Gerber M; Friedman P; Hodges S; Leissinger C
    Haemophilia; 2003 Jan; 9(1):110-5. PubMed ID: 12558787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100 degrees C heat after lyophilization.
    Santagostino E; Mannucci PM; Gringeri A; Azzi A; Morfini M; Musso R; Santoro R; Schiavoni M
    Transfusion; 1997 May; 37(5):517-22. PubMed ID: 9149778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequency of contamination of coagulation factor concentrates with novel human parvovirus PARV4.
    Schneider B; Fryer JF; Oldenburg J; Brackmann HH; Baylis SA; Eis-Hübinger AM
    Haemophilia; 2008 Sep; 14(5):978-86. PubMed ID: 18565125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of hepatitis C antibodies in patients with clotting disorders in Victoria. Relationship with other blood borne viruses and liver disease.
    Leslie DE; Rann S; Nicholson S; Fairley CK; Gust ID
    Med J Aust; 1992 Jun; 156(11):789-92. PubMed ID: 1321326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathogen safety of plasma-derived products - Haemate P/Humate-P.
    Gröner A
    Haemophilia; 2008 Nov; 14 Suppl 5(Suppl 5):54-71. PubMed ID: 18786011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parvovirus B19 transmission by heat-treated clotting factor concentrates.
    Blümel J; Schmidt I; Effenberger W; Seitz H; Willkommen H; Brackmann HH; Löwer J; Eis-Hübinger AM
    Transfusion; 2002 Nov; 42(11):1473-81. PubMed ID: 12421221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathogen inactivation and removal methods for plasma-derived clotting factor concentrates.
    Klamroth R; Gröner A; Simon TL
    Transfusion; 2014 May; 54(5):1406-17. PubMed ID: 24117799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Blood-transmitted viral infections among haemophiliacs in Tunisia].
    Langar H; Triki H; Gouider E; Bahri O; Djebbi A; Sadraoui A; Hafsia A; Hafsia R
    Transfus Clin Biol; 2005 Oct; 12(4):301-5. PubMed ID: 16099190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contamination of coagulation factor concentrates with human parvovirus B19 genotype 1 and 2.
    Schneider B; Becker M; Brackmann HH; Eis-Hübinger AM
    Thromb Haemost; 2004 Oct; 92(4):838-45. PubMed ID: 15467916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
    CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infection with hepatitis G virus among recipients of plasma products.
    Jarvis LM; Davidson F; Hanley JP; Yap PL; Ludlam CA; Simmonds P
    Lancet; 1996 Nov; 348(9038):1352-5. PubMed ID: 8918279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in clotting factor treatment for congenital hemorrhagic disorders.
    Tarantino MD; Aledort LM
    Clin Adv Hematol Oncol; 2004 Jun; 2(6):363-8. PubMed ID: 16163206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High frequencies of exposure to the novel human parvovirus PARV4 in hemophiliacs and injection drug users, as detected by a serological assay for PARV4 antibodies.
    Sharp CP; Lail A; Donfield S; Simmons R; Leen C; Klenerman P; Delwart E; Gomperts ED; Simmonds P
    J Infect Dis; 2009 Oct; 200(7):1119-25. PubMed ID: 19691429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Has hepatitis A virus been transmitted by clotting factor concentrates among hemophiliacs in the United States?
    Mosley JW
    Vox Sang; 1994; 67 Suppl 4():12-5; discussion 24-6. PubMed ID: 7831863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.